These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21498929)

  • 21. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
    Rajagopalan R; Xu Y; Abbadessa M;
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
    Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
    Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
    J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients.
    Genovese S; Passaro A; Brunetti P; Comaschi M; Cucinotta D; ; Egan CG; Chinea B; Bravi F; Di Pietro C
    J Endocrinol Invest; 2013 Sep; 36(8):606-16. PubMed ID: 23511244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.
    Schöndorf T; Karagiannis E; Posseldt RE; Forst T; Pfützner A
    Diabetes Technol Ther; 2009 Jun; 11(6):379-83. PubMed ID: 19459767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients.
    Igarashi M; Hirata A; Yamaguchi H; Jimbu Y; Tominaga M
    J Atheroscler Thromb; 2008 Feb; 15(1):34-40. PubMed ID: 18270461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
    Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
    Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes.
    Perez A; Khan M; Johnson T; Karunaratne M
    Diab Vasc Dis Res; 2004 May; 1(1):44-50. PubMed ID: 16305056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pioglitazone hydrochloride monotherapy or in combination with sulfonylurea therapy improves glycemia control in patients with type 2 diabetes].
    Yu Y; Li Y; Fan J; Wang Y; Yu H; Wang C; Liao Z; Gao H; Zhao W
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):117-20. PubMed ID: 15600200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
    Sharma SK; Verma SH
    J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
    Kashi Z; Mahrooz A; Kianmehr A; Alizadeh A
    PLoS One; 2016; 11(3):e0151543. PubMed ID: 26978661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea.
    Khaloo P; Asadi Komeleh S; Alemi H; Mansournia MA; Mohammadi A; Yadegar A; Afarideh M; Esteghamati S; Nakhjavani M; Esteghamati A
    J Endocrinol Invest; 2019 Jul; 42(7):851-857. PubMed ID: 30535871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
    Olansky L; Marchetti A; Lau H
    Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes.
    Jonker JT; Wang Y; de Haan W; Diamant M; Rijzewijk LJ; van der Meer RW; Lamb HJ; Tamsma JT; de Roos A; Romijn JA; Rensen PC; Smit JW
    Diabetes Care; 2010 Jul; 33(7):1625-8. PubMed ID: 20150294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen.
    Rendell MS; Glazer NB; Ye Z
    J Diabetes Complications; 2003; 17(4):211-7. PubMed ID: 12810245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus.
    Bays H; McElhattan J; Bryzinski BS;
    Diab Vasc Dis Res; 2007 Sep; 4(3):181-93. PubMed ID: 17907108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes.
    Tan MH; Johns D; Glazer NB
    Clin Chem; 2004 Jul; 50(7):1184-8. PubMed ID: 15117857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.